News
ZTS
164.41
-1.15%
-1.91
Zoetis Poised for Growth: Promising Innovations and Market Expansion Drive Buy Rating
TipRanks · 3h ago
Zoetis Highlights Growth at J.P. Morgan Conference
TipRanks · 1d ago
Weekly Report: what happened at ZTS last week (0106-0110)?
Weekly Report · 2d ago
Zoetis’s Market Potential Boosted by Librela’s US Launch and Shifting OA Treatment Trends
TipRanks · 2d ago
Top 50 High Quality Dividend Growth Stocks - January 2025
Seeking Alpha · 2d ago
Dividend Champion, Contender, And Challenger Highlights: Week Of January 12
Seeking Alpha · 4d ago
How Is The Market Feeling About Zoetis?
Benzinga · 4d ago
Are Investors Undervaluing Zoetis Inc. (NYSE:ZTS) By 33%?
Simply Wall St · 4d ago
Zoetis (ZTS) Surpasses Market Returns: Some Facts Worth Knowing
NASDAQ · 6d ago
Is Zoetis Inc. (NYSE: ZTS) Overvalued? Or Is It Worth Buying Now?
PR Newswire · 01/07 21:15
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Seeking Alpha · 01/07 16:31
Zoetis Is Maintained at Buy by Stifel
Dow Jones · 01/07 15:47
Zoetis Price Target Cut to $180.00/Share From $210.00 by Stifel
Dow Jones · 01/07 15:47
Stifel Maintains Buy on Zoetis, Lowers Price Target to $180
Benzinga · 01/07 15:37
ClearBridge Large Cap Growth Strategy Q4 2024 Commentary
Seeking Alpha · 01/07 15:20
Here's How Much You Would Have Made Owning Zoetis Stock In The Last 10 Years
Benzinga · 01/07 14:30
Press Release: Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2024 Financial Results
Dow Jones · 01/07 13:32
Stifel Nicolaus Reaffirms Their Buy Rating on Zoetis (ZTS)
TipRanks · 01/07 12:46
High quality cyclical stocks according to Morgan Stanley
Seeking Alpha · 01/06 19:57
Wells Fargo spotlights 31 names it believes ‘offer above-average growth potential’
Seeking Alpha · 01/06 19:32
More
Webull provides a variety of real-time ZTS stock news. You can receive the latest news about Zoetis Inc through multiple platforms. This information may help you make smarter investment decisions.
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. It is engaged in commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).